Abstract Guidelines

Print Friendly, PDF & Email

General Information
Abstract and Author Requirements
Resolution of Personal Conflicts of Interest
Formatting Your Abstract
Help with the Online Submission Form
Embargo and Copyright Policy
Publication
List of Subject Categories
Affiliation Abbreviations
Drug Names


General Information

  • Authors do not have to be members of one of the four sponsoring societies (IDSA, SHEA, PIDS, and HIVMA) to submit an abstract.
  • Submissions with “INCOMPLETE” status cannot be processed.
  • Submitters may return to the online system to edit abstracts, revise information, correct typographical errors, tables, graphics, or delete a submission at any time before the submission deadline May 17, 2017, 5 p.m. EDT.  After this time, the system will be closed, and complete abstracts reviewed by IDWeek.  An author may not revise or resubmit an abstract in order to make changes or corrections after this deadline; adding or removing authors after the submission deadline is not permitted.  The abstract may be withdrawn or, if accepted, the error may be indicated during the presentation.  Proofread abstracts carefully to avoid errors before they are submitted.  IDWeek is not authorized to make changes to a submission.  This includes typographical errors.  Your abstract, if selected, will be published exactly as submitted.  Tables and graphics, if the quality submitted is poor, will also appear badly.  If you choose to withdraw an abstract after the submission deadline, this request must be received by IDWeek in writing and sent to abstracts@idweek.org by July 14, 2017.  After this date, withdrawals are still accepted but abstracts may still appear in publications.  Withdrawal of an accepted after July 14, 2017 or failure to present an accepted abstract could result in disqualification from presenting an abstract at IDWeek for the subsequent year.
  • General information subject to change due to circumstances beyond IDWeek’s control.

Back to top


Abstract and Author Requirements

  • Obtain approval in advance from all co-authors before placing their names on the abstract. Submission of an abstract denotes that co-authors as well as authors have read the abstract, take responsibility for its content, and approve that their names appear on the abstract. Failure to obtain approval from all authors will result in immediate rejection of the abstract.
  • Include a concise statement of the research under investigation and its objectives. Define all concepts and abbreviations at first use.
  • Describe experimental methods briefly (including relevant numbers of patients and/or microorganisms).
  • Describe specific findings and analysis of data. (Promises such as “to be completed” are not acceptable.)
  • Include specific conclusions, with supporting statistical analyses when appropriate. (Concluding
    statements such as “the results will be discussed” are not acceptable.)
  • Do not submit multiple abstracts on overlapping facets of the same project unless each abstract has important, novel information and clearly stands on its own. Repetitive abstracts will be rejected.
  • Abstracts must not be submitted if previously presented at a national or international meeting such as IDSA, SHEA, ASTMH, ICAAC, ASM, CROI, or ECCMID. Abstracts that have been previously presented, but include updated information with significant new implications will be considered.
  • Resolve any issues relating to patent matters before submitting the abstract.
  • Agree to the IDWeek embargo and copyright policy.
  • Provide disclosures of potential conflicts of interest and complete an attestation form. List any financial interests, assistance, or relationships with companies, supporters, or commercial products that are related to the research (for example, research support, grants, sponsors, stockholder, etc.). A response to this request must be provided for each author or author group before the abstract can be peer reviewed.

Back to top


Resolution of Personal Conflicts of Interest

It is the policy of IDWeek that all faculty, abstract authors, and staff disclose and resolve any real or apparent conflicts of interest relating to the topics of this educational activity. According to the Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards, IDSA must provide balance, objectivity, and scientific rigor in all sponsored educational activities accredited for continuing medical education (CME). The intent of the disclosure is to provide the audience with information on which they can make their own judgments on program content.

 

The Infectious Diseases Society of America is accredited by ACCME to provide CME for physicians.

Back to top


Formatting Your Abstract

  • Abstracts should be no more than 1,950 characters; not including title, authors, and spaces. Characters within a table are counted towards the character limit. Figures, title, and authors do not count against the 1,950 character limit.  Use simple fonts.
  • Italics, underline, bold, superscript and subscript formatting, Greek characters (both upper and lowercase), scientific characters, charts, tables, and graphs are accepted.
  • Always include the abstract title, authors, affiliations, and text.
  • You may upload a file or copy and paste the text of your abstract from a word processing document or a clipboard directly into the online abstract box.
  • Figures are accepted and they do not count towards character limit. You are limited to three images in one abstract. There isn’t a maximum allowed resolution for figures. The maximum size for an abstract  is 5120 KB including images. If you choose to include images, you must upload the abstract in html format, images can be in any file type. Color images are allowed.
  • All fields must contain the requested information or the submission will not be complete.
  • Do not send multiple submissions of the same abstract. Duplicate abstracts will be rejected. Be sure to combine all new information into one abstract.
  • Always keep an original copy of your submitted abstract.
  • Always proofread your abstract. Accepted abstracts will be published as submitted. If English is not your first language, please have a fluent English speaker review your abstract for conference abstract editing. Please note that edited abstracts will still need to undergo peer-review by IDWeek.

Back to top


Help with the Online Submission Form

The following is required to complete the online submission. Please note, detailed instructions are provided online during the abstract submission process.

TITLE: Use a concise title that summarizes the content of the abstract. Capitalize the first letter of each word except prepositions, articles, and species names. Italicize all specific/scientific names of microorganisms as appropriate.

SUBJECT CATEGORY: Select up to two subject categories. Abstracts will be divided into categories for review and programming purposes. The IDWeek Program Committee reserves the right to reassign your abstract to a different category if deemed necessary.

KEY WORDS: Choose one to three key words in the menu (highest priority first). Additional key words are accepted but should be words in common usage, such as those used in Medline and Index Medicus.

AUTHORS: Enter complete author(s) names (example: John S. Doe, MD). Include the name, degree, institution, city, state, and country of all authors and author groups.

AFFILIATIONS: List the name of each author’s institution, city, state, and country (do not include department, division, laboratory, etc.). Grant acknowledgments should not appear in abstracts, but should be included in the CME disclosures.

ABSTRACT TEXT: Describe the relevance of the research using background, methods, results, and conclusions. IDWeek will not edit or revise the abstracts. Submitters/authors are responsible for the accuracy of the abstract text. We recommend that a colleague review the abstract for accuracy and grammar.

CONTACT INFORMATION: Provide all pertinent contact information to ensure that correspondence is received promptly and accurately. You must specify the “presenting author.” IDWeek will correspond with the presenting author using only the contact information that is provided at the time of submission. It is the responsibility of the presenting author to communicate future correspondence to all co-authors. Notifications will be sent to the presenting author only.

CHANGES/MODIFICATIONS: Changes/modifications, including author and affiliation changes, are allowed for submitted abstracts until the abstract submission deadline, 5 p.m. EDT on Wednesday, May 17, 2017. Changes to submitted abstracts will not be possible after the submission deadline. Once you submit the abstract, a confirmation message will appear on the screen with an abstract tracking number assigned. Keep a record of your abstract tracking number until you receive your abstract disposition letter.

Back to top


Embargo and Copyright Policy

Abstracts are considered official communications of the conference. The presenting author and co-authors must comply with the IDWeek embargo policy that abstracts must be based on results that have not been previously published and are not anticipated to be published before the meeting UNLESS the publication occurs AFTER the abstract submission deadline but prior to July 31, 2017. Authors should inform IDWeek if the results are published at any time after submission. Abstracts must not be submitted if previously presented at a national or international meeting such as IDSA, SHEA, ICAAC, ASM, CROI, ASMMicrobe, or ECCMID. The IDWeek Program Committee will consider abstracts that have been previously submitted at smaller/regional meetings, but have not been published in a journal and on the proviso that no rights have previously been transferred; however, all new or updated data must be included in the abstract.

 

Authors and co-authors transfer any copyrights and agree to release the abstract for future IDWeek publication and grant permission to IDWeek to audio/video record oral presentations for later sale or publication.  IDWeek owns the copyrights to all abstracts accepted for presentation in perpetuity.

 

Please note: In submitting your abstract you also warrant that you have exercised reasonable care to ensure that the article is accurate and does not contain anything which is libellous, or obscene, or infringes on anyone’s copyright, right of privacy, or other rights. All abstracts must be embargoed until Wednesday, October 4, 2017 at 12:01 a.m. PDT, with the exception of research findings presented at IDWeek press conferences.

Back to top


Publication

IDWeek 2017 abstracts will be published as an online supplement to Open Forum Infectious Diseases (OFID), the new Open Access Journal from IDSA. They will be permanently archived as part of the journal and will be accessible to all journal readers, not only meeting attendees or society members. Abstracts will also be available in the IDWeek Interactive Program, and in the official IDWeek app for iPhone and Android. If you do not want your abstract included in OFID, the Interactive Program, or the app, you must withdraw your abstract completely from the meeting by July 14, 2017.

Back to top


List of Subject Categories

A: Antimicrobial Agents Including Antibacterial, Antiviral and Antifungal Drugs

A1. Novel agents
A2. PK/PD studies
A3. Resistance mechanisms
A4. Treatment antimicrobial resistant infections
A5. Pharmacogenetics

 

B: Basic Science and Translational Studies of Microbial Pathogenesis and Infectious Diseases

B1. Studies of correlates of protection (or biomarkers) against microbial infection and disease in patients or experimental models.
B2. Studies of the immune response to microbial infection and disease in patients or experimental models.
B3. Studies of genetic factors that govern susceptibility to microbial infection and disease.
B4. Studies of microbial factors that govern susceptibility to microbial infection and disease.
B5. Studies at the interface of host-microbe interaction.
B6. Microbiome science

 

C: Clinical Infectious Diseases

C1. Clinical trials (abstracts submitted to C1. should choose a secondary category that describes the subject matter of the trial)
C2. Bone and joint, skin and soft tissue
C3. Respiratory infections
C4. Enteric infection
C5. Bacteremia and endocarditis
C6. CNS infection
C7. Sexually transmitted Infections
C8. UTIs

D: Infectious Disease Diagnostics (e.g., all aspects of adult and pediatric diagnostic microbiology, rapid diagnostics, molecular diagnostics, host response signatures as diagnostics, molecular imaging, nanotechnology, next generation sequencing, genomics/proteomics, and other advanced technologies for detection of infectious diseases)

D1. Bacteriology/mycobacteriology
D2. Virology
D3. Parasitology
D4. Mycology
D5. Typing/sequencing
D6. Other (e.g., host response biomarkers, molecular imaging, metabolomics/proteomics, etc.)

 

E: Infectious Diseases Medical Education (scholarly work directed at enhancing infectious diseases education of trainees and/or health professionals)

 

F: Hepatitis (all HIV co-infection abstracts should be submitted to Category H)

F1. Hepatitis A
F2. Hepatitis B
F3. Hepatitis C
F4. Hepatitis E

 

G: Global Health (e.g., travel medicine, tropical medicine and parasitology, endemic/epidemic diseases of resource-challenged areas )

 

H: HIV/AIDS, other retroviruses, and co-infections

H1. Epidemiology and screening
H2. Prevention
H3. Pathogenesis
H4. Treatment
H5. Complications and co-infections

 

I: Adult and Pediatric Vaccines

I1. Adult Vaccines
I2. Pediatric Vaccines
I3. Adolescent Vaccines

 

J: Clinical Practice Issues (e.g., billing, medical records & informatics, healthcare reform, home health/OPAT)

 

K: Tuberculosis and other Mycobacterial Infections

 

L: New Agents/Trials

L1. New drug development
L2. New diagnostics
L3. New vaccines

 

M: Medical Mycology

M1. Clinical studies of fungal infections
M2. Studies of fungal pathogenesis in patients with immune impairment
M3. Studies of the pathogenesis of fungal infections

 

N: Healthcare Epidemiology and Prevention

N1. Occupational health
N2. HAI Surveillance and public reporting
N3. Epidemiologic methods
N4. Device-related HAIs (CLABSI, CAUTI, VAP)
N5. The environment (e.g., source control and device processing)
N6. Hand hygiene
N7. Surgical site infections
N8. Clostridium difficile
N9. MRSA, MSSA and other gram positive pathogens
N10. MDRO-GNR/emerging resistant bacterial pathogens
N11. HAI outbreaks (and other types of HAIs)
N12. Non-acute care (e.g. long-term care, ambulatory settings, dialysis centers, visiting nursing)
N13. Resource constrained environments (e.g., infection prevention, surveillance)

 

O: Public Health (Studies on issues pertaining to preparedness for and response to outbreaks of infectious diseases including those linked to agents of bioterror, foodborne, waterborne, vectorborne, zoonotic diseases, and vaccine-preventable diseases)

 

P: Pediatric and Perinatal Infections

P1. Bacterial studies (natural history and therapeutic)
P2. Fungal studies (natural history and therapeutic)
P3. Viral studies (natural history and therapeutic)
P4. Antimicrobial stewardship (inpatient/outpatient pediatric focused)
P5. Healthcare-associated infection epidemiology and prevention
P6. HIV
P7. Maternal-child infections

 

S: Antimicrobial Stewardship, including quality of care

S1. Antimicrobial stewardship program development and implementation
S2. Antimicrobial stewardship outcomes assessment (clinical and economic)

 

T: Transplant and Immunocompromised Host Infections

T1. Studies of pre-transplant screening and evaluation.
T2. Studies of empiric and pre-emptive therapy.
T3. Studies of the epidemiology of infections in transplant patients and patients with impaired immunity due to underlying disease or immunosuppressive drugs.

 

V: Virology (all viruses other than HIV, HIV co-infections, and hepatitis)

V1. Studies of the epidemiology of viral infections
V2. Studies of viral pathogenesis
V3. Studies of treatment and prevention of viral infections

Back to top


Affiliation Abbreviations

Administration Admin.
Biology or Biological Biol.
Center Ctr.
Centers for Disease Control and Prevention CDC
Clinic or Clinical Clin.
College Coll.
Corporation Corp.
Development Dev.
Education Ed.
U.S. Food and Drug Administration U.S. FDA
Foundation Fndn.
General Gen.
Hospital(s) Hosp.
Incorporated Inc.
Institute(s) or Institution Inst.
International Intl.
Medical or Medicine Med.
Memorial Mem.
Microbiology or Microbiological Microbiol.
National Natl.
National Cancer Institute NCI
National Institutes of Health NIH
National Institute of Allergy and Infectious Diseases NIAID
Public Publ.
Research Res.
School Sch.
Science(s) Sci.
University Univ.
U.S. Department of Agriculture U.S. DA
Veterans Administration Vet.

 Back to top


Drug Names

Drug products mentioned in the abstract should be identified by their non-proprietary (e.g., generic) name only. Do not capitalize non-proprietary names.

Back to top

 

ADVERTISEMENT

ADVERTISEMENT